Ucb S.a. · EURONEXT:UCB
Ucb — Shareholder Meeting (April 2021)
12 slides from Ucb's shareholder meeting presentation, Apr 29, 2021
Slide 1: UCB General Meeting of Shareholders
UCB General Meeting of Shareholders 29 April 2021
Slide 2: A word from Jean-Christophe Tellier, CEO UCB
A word from Jean-Christophe Tellier CEO UCB
Slide 3: Covid Pandemic Accelerates Key Trends
Covid Pandemic Accelerates Key Trends 2020 FY - 3 Trends that shape our external environment Faster pace of innovation Digital Transformation Increasing uncertainty around Sustainability and Societal Access, Pricing, Demand and global Value Aspirations supply networks
Slide 4: Integrating Sustainability - Our Business Approach
2020 FY - 4 Integrating Sustainability - Our Business Approach
Slide 5: Deliver care where it's needed
Deliver care where it’s needed
Slide 6: Sustain growth
Sustain growth 6
Slide 7: Strong underlying net sales growth
Strong underlying net sales growth 2020 FY - 7 Resilient Product Portfolio & New Launches Act CER Cimzia® € 1 799 million +5% +7% 2020 FY net sales* Driven by new patient populations € 5 023 million +5% (+7% CER) Vimpat® € 1 451 million +10% +12% Strong, sustainable growth in all markets Vimpat Kepp
Slide 8: Our ability to deliver
Our ability to deliver (Q» (Ue (@ Q) WY) (a) Focus on patients Strengthen Identify & act on who can benefit most our R&D* potential opportunities es ~ oe 2 cimzia —- VIMPAT (Certokzumat pega!) eriiact® fom 2 launches a @>EVENITY Nayzilamce (romosazumab-aqqg) (midazolam) nasal spray Bimekizumab posit
Slide 9: UCB's rich development pipeline
UCB's rich development pipeline 9 All timelines confirmed Phase 1 Phase 2 Phase 3 Filing bimekizumab (IL17A/F) psoriasis (PsO) Filing (U.S. & EU) psoriatic arthritis (PsA) Topline results end 2021 axial spondyloarthritis (AxSpA) Topline results end 2021 hidradenitis suppurativa (HS) Topline results
Slide 10: Where we aim to be in 2025+
10 Leadership in 5 specific patient populations Financial outlook: at least € 6 billion top line, 2025 Where we low – mid-thirties EBITDA margin aim to be 2030 targets from UCB’s green strategy: Be carbon neutral -20% water withdrawal 2030 in 2025+ -25% waste production (base 2015)
Slide 11: Board of Directors
11 Evelyn du Monceau Pierre Gurdjian Jean-Christophe Tellier Jan Berger Kay Davis Charles-Antoine Albrecht De Graeve Roch Doliveux Susan Gasser Cyril Janssen Janssen Board of Viviane Monges Cédric van Rijckevorsel Ulf Wiinberg Directors
Slide 12: A Word from Evelyn du Monceau
A Word from Evelyn du Monceau 12